Salesforce Inc vs DENTSPLY SIRONA Inc — how do they compare? Salesforce Inc trades at $228.6 (market cap $187.48B), while DENTSPLY SIRONA Inc trades at $8.61 (market cap $1.73B). The key difference: Salesforce Inc is far larger — about 108.4× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| CRM | XRAY | |
|---|---|---|
Market Cap | $187.48B | $1.73B |
Volume | 6,155,822 | 6,198,582 |
Sector | Technology | Health |
52-Week High | $266.23 | $14.68 |
52-Week Low | $150.12 | $8.52 |
Typical Hold Time | 89 Days | 72 Days |
Enterprise Value | $217.82B | $3.80B |
Dividend Yield | 0.77% | 5.04% |
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $224.56, down 0.19% on the day, amid a broader software sector sell-off driven by AI disruption concerns. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $5.90 vs. $3.27 expected) and robust profitability (77.28% gross margin, 21.99% net margin). Technical indicators signal bearish momentum with resistance at $227 and support at $222. Recent news highlights AI-driven volatility but also underscores Salesforce's positioning as an Agentic AI beneficiary.
Outlook: Salesforce's discounted valuation (P/E 20.86 vs. historical averages) and AI monetization growth (Agentforce ARR up 200% YoY) present a buying opportunity, though near-term risks include sector-wide pressure and macroeconomic uncertainty. Analyst consensus remains strongly bullish with a $271.91 price target, suggesting ~21% upside.
DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →